BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 14638850)

  • 1. Phase II trial of gefitinib in recurrent glioblastoma.
    Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
    J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
    Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
    Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
    Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
    J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
    Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
    J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
    Schilder RJ; Sill MW; Chen X; Darcy KM; Decesare SL; Lewandowski G; Lee RB; Arciero CA; Wu H; Godwin AK
    Clin Cancer Res; 2005 Aug; 11(15):5539-48. PubMed ID: 16061871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
    Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
    Schwer AL; Kavanagh BD; McCammon R; Gaspar LE; Kleinschmidt-De Masters BK; Stuhr K; Chen C
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1352-7. PubMed ID: 19013723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
    Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.